천식 환자의 일상 임상 진료에서 질환 특성 및 결과 평가 연구 (AIRITY)
혼합된 횡단면 및 전향적 연구: 천식 환자의 실제 임상 환경에서 환자 특성, 질병 부담, 질병 조절, 표현형, 내인형 및 결과 평가
The main aim of the study to describe the characteristics of participants with asthma across the spectrum of disease severity, including sociodemographic and clinical characteristics, treatment and disease burden, biomarkers, and both disease-specific and generic health-related quality of life.
The study consists of two parts: a cross-sectional study, and a prospective follow-up evaluate changes in disease trajectories in participants with asthma.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Trial Transparency email recommended-Toll free for US & Canada
- 전화번호: 6 800-633-1610
- 이메일: Contact-US@sanofi.com
연구 장소
-
-
Bayern (Bavaria)
-
München, Bayern (Bavaria), 독일, 85039
- 모병
- Investigational Site Number: 276503
-
-
North Rhine-Westphalia
-
Bonn, North Rhine-Westphalia, 독일, 53119
- 모병
- Investigational Site Number: 276505
-
-
Saxony
-
Hohenstein-Ernstthal, Saxony, 독일, 09337
- 모병
- Investigational Site Number: 276501
-
-
Schleswig-Holstein
-
Schleswig, Schleswig-Holstein, 독일, 24837
- 모병
- Investigational Site Number: 276502
-
-
-
-
Alabama
-
Bessemer, Alabama, 미국, 35022
- 모병
- Trinity Clinical Research, LLC - Bessemer - Site Number: 840150
-
-
Arizona
-
Chandler, Arizona, 미국, 85224
- 빼는
- Chandler Clinical Trials - Site Number: 840106
-
Mesa, Arizona, 미국, 85206
- 모집하지 않고 적극적으로
- Del Sol Research Management, LLC - Mesa - Site Number: 840123
-
Scottsdale, Arizona, 미국, 85254
- 모병
- Orso Health - Scottsdale - Site Number: 840133
-
Sun City, Arizona, 미국, 85351
- 모집하지 않고 적극적으로
- Sun City Clinical Trials - Elite - Site Number: 840120
-
-
California
-
California City, California, 미국, 91107
- 모집하지 않고 적극적으로
- FOMAT - Huntington Asthma & Allergy Center - Site Number: 840158
-
La Palma, California, 미국, 90623
- 모집하지 않고 적극적으로
- Imax Clinical Trials - Site Number: 840109
-
Los Angeles, California, 미국, 90017
- 모집하지 않고 적극적으로
- Downtown LA Research - Site Number: 840161
-
Newport Beach, California, 미국, 92663
- 모집하지 않고 적극적으로
- Newport Native MD, Inc. - Site Number: 840101
-
Pasadena, California, 미국, 91101
- 모집하지 않고 적극적으로
- Pasadena Clinical Trials - Site Number: 840116
-
Tarzana, California, 미국, 91356
- 빼는
- Valiance Clinical Research (JPJ Research) - Site Number: 840135
-
Walnut Creek, California, 미국, 94598
- 모집하지 않고 적극적으로
- Clinical Research of California - Site Number: 840145
-
-
Florida
-
Altamonte Springs, Florida, 미국, 32701
- 모집하지 않고 적극적으로
- Cornerstone Research Institute, LLC - Site Number: 840152
-
Boca Raton, Florida, 미국, 33431
- 모집하지 않고 적극적으로
- 3SYNC Research - Boca Raton - Site Number: 840148
-
Brandon, Florida, 미국, 33511
- 모집하지 않고 적극적으로
- Meris Clinical Research - Site Number: 840167
-
Greenacres City, Florida, 미국, 33467
- 모집하지 않고 적극적으로
- Finlay Medical Research - Site Number: 840107
-
Miami, Florida, 미국, 33126
- 모집하지 않고 적극적으로
- EMDA Clinical Research - Site Number: 840113
-
Miami, Florida, 미국, 33126
- 모집하지 않고 적극적으로
- Finlay Medical Research - Miami - Site Number: 840110
-
Miami, Florida, 미국, 33130
- 모집하지 않고 적극적으로
- Care Research Inc. - Site Number: 840103
-
Miami, Florida, 미국, 33142
- 모집하지 않고 적극적으로
- L&A Morales Healthcare, Inc - Site Number: 840102
-
Miami, Florida, 미국, 33145
- 모집하지 않고 적극적으로
- MedOne Clinical Research - Site Number: 840122
-
Miami, Florida, 미국, 33155
- 모집하지 않고 적극적으로
- D&H National Research Centers INC - Site Number: 840128
-
Miami, Florida, 미국, 33173
- 모집하지 않고 적극적으로
- Research Institute Of South Florida - Site Number: 840149
-
Miami, Florida, 미국, 33174
- 모집하지 않고 적극적으로
- Valencia Medical & Research Center, Corp - Site Number: 840153
-
Miami, Florida, 미국, 33186
- 모집하지 않고 적극적으로
- Correa Research Center, Inc. - Site Number: 840141
-
Miami Gardens, Florida, 미국, 33014
- 모집하지 않고 적극적으로
- Pro Care Research Center - Site Number: 840143
-
Miami Lakes, Florida, 미국, 33014
- 모집하지 않고 적극적으로
- 3SYNC Research - Miami Lakes - Site Number: 840146
-
Miami Lakes, Florida, 미국, 33014
- 모집하지 않고 적극적으로
- Deluxe Health Center - Site Number: 840117
-
Miami Lakes, Florida, 미국, 33016
- 모집하지 않고 적극적으로
- MedQuest Translation Sciences, LLC - Site Number: 840162
-
North Miami Beach, Florida, 미국, 33169
- 모집하지 않고 적극적으로
- Biscayne Clinical Research - Site Number: 840157
-
Palm Springs, Florida, 미국, 33406
- 모집하지 않고 적극적으로
- CTMD Research, Inc - Site Number: 840147
-
Plantation, Florida, 미국, 33317
- 모집하지 않고 적극적으로
- Edward Jenner Research Group, LLC - Site Number: 840169
-
Port Saint Lucie, Florida, 미국, 34986
- 모집하지 않고 적극적으로
- Mark J. Pamer D.O., LLC - Site Number: 840121
-
Tamarac, Florida, 미국, 33321
- 모집하지 않고 적극적으로
- TBC Research Corp - Site Number: 840132
-
Tampa, Florida, 미국, 33613
- 모집하지 않고 적극적으로
- Avita Clinical Research - Tampa - Site Number: 840125
-
West Palm Beach, Florida, 미국, 33409
- 모집하지 않고 적극적으로
- Palm Beach Medical & Research Center, Inc. - Site Number: 840165
-
-
Georgia
-
Columbus, Georgia, 미국, 31904
- 모집하지 않고 적극적으로
- The Allergy Center at Brookstone - Site Number: 840114
-
-
Illinois
-
Chicago, Illinois, 미국, 60616
- 모집하지 않고 적극적으로
- Next Innovation Clinical Research - Chicago - Site Number: 840159
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40509
- 모집하지 않고 적극적으로
- Bluegrass Allergy Care - Lexington - Site Number:840112
-
-
Maryland
-
Columbia, Maryland, 미국, 21045
- 모병
- Columbia Medical Practice - Site Number: 840172
-
Rockville, Maryland, 미국, 20854
- 모집하지 않고 적극적으로
- Velocity Clinical Research - Rockville - Site Number: 840163
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 모병
- University of Michigan - Ann Arbor - Site Number: 840140
-
-
Montana
-
Missoula, Montana, 미국, 59808
- 모집하지 않고 적극적으로
- Montana Medical Research - Site Number: 840137
-
-
Nebraska
-
Papillion, Nebraska, 미국, 68046
- 모집하지 않고 적극적으로
- Primary Clinical Research, LLC - Papillion - Site Number: 840168
-
-
New Jersey
-
Sewell, New Jersey, 미국, 08080
- 모집하지 않고 적극적으로
- MedCorps Asthma and Pulmonary Specialists LLC - Sewell - Site Number: 840136
-
-
New York
-
Cortland, New York, 미국, 13045
- 모집하지 않고 적극적으로
- Finger Lakes Medical Research, PLLC - Site Number: 840155
-
New Windsor, New York, 미국, 12553
- 모집하지 않고 적극적으로
- Mid Hudson Medical Research, PLLC - Site Number: 840139
-
New York, New York, 미국, 10029
- 모집하지 않고 적극적으로
- Icahn School of Medicine at Mount Sinai - Center for Advanced Medicine - Site Number: 840119
-
-
North Carolina
-
Asheville, North Carolina, 미국, 28801
- 모집하지 않고 적극적으로
- Allergy Partners of Western North Carolina - Site Number: 840131
-
Gastonia, North Carolina, 미국, 28054-7489
- 모집하지 않고 적극적으로
- Clinical Research of Gastonia (CRG) - Site Number: 840160
-
Greenville, North Carolina, 미국, 27834-2849
- 모병
- East Carolina University Physicians - Pulmonary and Critical Care Medicine - Site Number: 840142
-
-
Ohio
-
Lima, Ohio, 미국, 45801
- 모집하지 않고 적극적으로
- NexGen Research - Site Number: 840154
-
Toledo, Ohio, 미국, 43617
- 모집하지 않고 적극적으로
- Toledo Institute of Clinical Research Inc - Site Number: 840105
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15241
- 모집하지 않고 적극적으로
- Allergy and Clinical Immunology Associates - Site Number: 840127
-
-
South Carolina
-
Rock Hill, South Carolina, 미국, 29732
- 모집하지 않고 적극적으로
- Clinical Research of Rock Hill - Site Number: 840115
-
-
Tennessee
-
Tennessee City, Tennessee, 미국, 30909
- 모집하지 않고 적극적으로
- Allergy Associates, PA dba Allergy, Asthma and Sinus Center - Site Number: 840144
-
-
Texas
-
Dallas, Texas, 미국, 75235
- 모집하지 않고 적극적으로
- Southwest Family Medicine Associates - Site Number: 840126
-
El Paso, Texas, 미국, 79902
- 모집하지 않고 적극적으로
- El Paso Pulmonary Association (EPPA) - West El Paso - Site Number: 840108
-
Houston, Texas, 미국, 77090
- 모집하지 않고 적극적으로
- Lumi Research - Site Number: 840156
-
Houston, Texas, 미국, 77099
- 모집하지 않고 적극적으로
- Pioneer Research Solutions - Site Number: 840104
-
Hurst, Texas, 미국, 76054
- 모집하지 않고 적극적으로
- Lumi Research - Hurst - Site Number: 840164
-
Tomball, Texas, 미국, 77081
- 모집하지 않고 적극적으로
- DM Clinical - Tomball - Site Number: 840130
-
-
Washington
-
Bellingham, Washington, 미국, 98225
- 모집하지 않고 적극적으로
- Bellingham Asthma, Allergy & Immunology Clinic - Site Number: 840138
-
-
-
-
-
Madrid, 스페인, 28034
- 모병
- Investigational Site Number: 724408
-
-
-
-
-
Niigata, 일본
- 모병
- Investigational Site Number: 392707
-
-
Fukuoka
-
Kitakyushu-Shi, Fukuoka, 일본, 802-0083
- 모병
- Investigational Site Number: 392705
-
-
Kagawa-ken
-
Takamatsu, Kagawa-ken, 일본, 761-8073
- 모병
- Investigational Site Number: 392702
-
-
Saga-ken
-
Saga, Saga-ken, 일본, 849-8501
- 모병
- Investigational Site Number: 392711
-
-
Tokyo
-
Bunkyo-ku, Tokyo, 일본, 113-8431
- 모병
- Investigational Site Number: 392710
-
tabashi City, Tokyo, 일본, 173-8610
- 모병
- Investigational Site Number: 392709
-
-
-
-
Alberta
-
Calgary, Alberta, 캐나다, T3R 1W7
- 모병
- Investigational Site Number: 124203
-
-
Ontario
-
Windsor, Ontario, 캐나다, N8X 2G1
- 모병
- Investigational Site Number: 124201
-
-
Quebec
-
Trois-Rivières, Quebec, 캐나다, G8T7A1
- 모병
- Investigational Site Number: 124204
-
-
-
-
Brittany Region
-
Brest, Brittany Region, 프랑스, 29200
- 모병
- Investigational Site Number: 250603
-
-
Occitanie
-
Lunel, Occitanie, 프랑스, 34400
- 모병
- Investigational Site Number: 250612
-
Toulouse, Occitanie, 프랑스, 31059
- 모병
- Investigational Site Number: 250607
-
-
Pays de la Loire Region
-
La Roche-sur-Yon, Pays de la Loire Region, 프랑스, 85000
- 모병
- Investigational Site Number: 250613
-
-
Île-de-France Region
-
Argenteuil, Île-de-France Region, 프랑스, 95100
- 모병
- Investigational Site Number: 250616
-
Créteil, Île-de-France Region, 프랑스, 94010
- 모병
- Investigational Site Number: 250609
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Enrollment into Part 1 is planned to achieve a balanced distribution of participants across participating regions, to the extent feasible. In addition, enrollment is intended to include pediatric participants, adolescents, and adults. Enrollment into Part 2 is planned to achieve a balanced distribution of participants across participating regions, to the extent feasible.
설명
Inclusion Criteria:
Applicable for Part 1 participants:
- Age 6 years and older, at the time of signing the informed consent
- Physician diagnosis of asthma for at least 12 months
- Existing treatment with low, medium, or high dose ICS and other asthma therapies as reflected in GINA 2-5 steps
- Participant or legally authorized representative (where applicable) has consented to participate
Applicable for Part 2 participants:
- Age 18 years and older, at the time of signing the informed consent.
- Physician diagnosis of asthma for at least 12 months
- Existing treatment with low or medium ICS and other asthma therapies as reflected in GINA 2-4 steps
- Participant or legally authorized representative (where applicable) has consented to participate
- Participants must meet the criteria for at least one of the cohorts below:
A) Asthma control cohorts
- ACQ-5 >= 1.5
- ACQ-5 < 1.5 (B) Type-2 biomarker cohorts
- Elevated T2 biomarkers (B1: Type-2-high cohort)
- Low T2 biomarkers (B2: Type-2-low cohort)
Participants are excluded from the study if any of the following criteria apply (applicable for both Part 1 and Part 2 participants):
- Current diagnosis of chronic obstructive pulmonary disease (COPD) or congestive heart failure
- Participants with moderate/severe cognitive impairment.
- Participants with moderate/severe cardiac disease.
- Participants on immunosuppressive medication for a chronic condition.
- Participation in other interventional and noninterventional clinical study (currently or in the past 3 months)
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
Part-1: Participants With Asthma
Participants receiving treatment with low-, medium-, or high-dose inhaled corticosteroids (ICS) and/or biologic therapies as part of standard of care (SoC) for the management of asthma in routine clinical practice. |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: A1- Uncontrolled Asthma Cohort
Participants receiving SoC with Asthma Control Questionnaire-5 (ACQ-5) threshold of greater than or equal to (>=)1.5 |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: A2- Controlled Asthma Cohort
Participants receiving SoC with Asthma Control Questionnaire-5 (ACQ-5) threshold of less than (<)1.5 |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: B1- Type-2 (T2) High Asthma Cohort
Participants receiving SoC with elevated T2 biomarkers |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: B2- Type-2 Low Asthma Cohort
Participants receiving SoC with low T2 biomarkers |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 1: Descriptive Characterization of Participants With Asthma Across the Spectrum of Severities
기간: Part 1: At baseline
|
Descriptive Statistical Analyses may include sociodemographic and clinical characteristics, comorbidities, exacerbation history, medication burden, biomarkers and lung function. |
Part 1: At baseline
|
|
Part 1: ACQ-5 Scores to Evaluate Characteristics of Participants With Asthma
기간: Part 1: At baseline
|
ACQ-5 is a 5-question survey. The five ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), and the overall score is the mean of the five responses. Participant's scores are then classified into three prescribed groups as having well-controlled asthma (score ≤ 0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). A change in ACQ-5 score of 0.5 is considered the minimal clinically important difference (MCID) |
Part 1: At baseline
|
|
Part 1: Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) Scores to Evaluate Characteristics of Participants With Asthma
기간: Part 1: At baseline
|
The Asthma Quality of Life Questionnaire (AQLQ) includes 32 items, The mini-AQLQ is a reduced version of the AQLQ which includes 15 items. The questions correspond to 4 dimensions of health: symptoms (5 items), limitation of usual activities (4 items), emotional function (3 items) and environmental stimuli (3 items). The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability. Higher scores indicating better quality of life (less impairment) and lower scores indicating worse quality of life (greater impairment). |
Part 1: At baseline
|
|
Part 1: Physician Global Assessment of Asthma Severity and Symptom Control
기간: Part 1: At baseline
|
Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: Physician Global Impression of Severity (PhGIS) - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity. |
Part 1: At baseline
|
|
Part 2: Descriptive Statistical Analysis of Difference in Asthma Symptom Control (ACQ-5) Between Part 2 Cohorts A1 and A2
기간: Part 2: At Weeks 52 and 104
|
Data on participant's asthma symptoms and control will be collected via the ACQ-5, 5-question survey. The five ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), and the overall score is the mean of the five responses. Participant's scores are then classified into three prescribed groups as having well-controlled asthma (score <=0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). A change in ACQ-5 score of 0.5 is considered the MCID. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Number of Participants Analyzed with Treatment Utilization Pattern between Part 2 Cohorts A1 and A2
기간: Part 2: At Weeks 52 and 104
|
Treatment utilization will include systemic corticosteroids (SCS), ICS, and short-acting beta agonists (SABA). Number of participants with various treatment utilization pattern will be assessed and reported. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Descriptive Statistical Analysis of Difference in Change in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV₁) between Part 2 Cohorts B1 and Cohort B2
기간: Part-2: At Weeks 52 and 104
|
Pre-BD FEV₁ is the forced expiratory volume in 1 second measured by spirometry prior to bronchodilator administration. |
Part-2: At Weeks 52 and 104
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
1부: 인구통계학적 특성과 임상적 특성에 따라 분류된 참가자 수
기간: 1부: 연구 등록 12개월 전부터
|
1부: 연구 등록 12개월 전부터
|
|
|
Part 1: 질병 부담, 건강 상태, 치료 경험에 따라 특성화된 참가자 수
기간: 1부: 연구 등록 12개월 전부터
|
1부: 연구 등록 12개월 전부터
|
|
|
파트 1: 약물 사용으로 특성화된 참가자 수
기간: 파트 1: 연구 등록 12개월 전부터
|
파트 1: 연구 등록 12개월 전부터
|
|
|
제1부: 생활방식과 환경적 영향에 따라 특성화된 참가자 수
기간: 1부: 연구 등록 12개월 전부터
|
1부: 연구 등록 12개월 전부터
|
|
|
1부: 흡입 및 전신 코르티코스테로이드 사용에 따른 참가자 수
기간: Part 1: 연구 등록 12개월 전부터
|
Part 1: 연구 등록 12개월 전부터
|
|
|
파트 1: 의료 자원 이용(HCRU)에 의해 특성화된 참가자 수
기간: 파트 1: 연구 등록 12개월 전부터
|
파트 1: 연구 등록 12개월 전부터
|
|
|
2부: 사회인구학적 특성, 질환 특성 및 치료 이력을 포함한 기술적 특성화
기간: 파트 2: 기준 방문 시
|
파트 2: 기준 방문 시
|
|
|
2부: 52주 및 104주차의 연간 악화율
기간: 파트 2: 52주 및 104주째
|
파트 2: 52주 및 104주째
|
|
|
파트 2: 흡입 및 전신 코르티코스테로이드 부담의 변화에 대해 분석된 참가자 수
기간: 2부: 기준 시점부터 104주 차까지
|
2부: 기준 시점부터 104주 차까지
|
|
|
Part 2: 바이오마커 수준의 변화
기간: 구간 2: 52주 및 104주에
|
구간 2: 52주 및 104주에
|
|
|
Part 1: Physician-Reported Outcomes to Characterize Physician Perspectives
기간: Part 1: From 12 months prior to study enrollment
|
The treatment preferences for participant profiles, an assessment of perceived disease burden on participants, an evaluation of barriers to optimal treatment, and treatment adherence and persistence will be collected from the main treating physician. |
Part 1: From 12 months prior to study enrollment
|
|
Part 1: Change From Baseline in Patient Global Impression of Severity (PGIS) Score
기간: Part 1: From 12 months prior to study enrollment
|
The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity. |
Part 1: From 12 months prior to study enrollment
|
|
Part 1: Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Score
기간: Part 1: From 12 months prior to study enrollment
|
The WPAI-Asthma is an Asthma-specific, patient-reported measure of work absenteeism, work presenteeism (reduced productivity while working due to illness), total work productivity loss (absenteeism plus presenteeism), and overall activity impairment over the prior 7 days. The WPAI-Asthma questionnaire score represents the percentage of impairment, from 0 to 100%. Higher scores represent greater impairment and less productivity. |
Part 1: From 12 months prior to study enrollment
|
|
Part 2: Changes From Baseline to Week 104 in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
기간: Part 2: From baseline to week 52 and week 104
|
FEV1 will be measured in Liters. Change from baseline: mean of (value of observed FEV1 at treatment duration minus baseline value). |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Number of Participants With Significant Changes in Asthma Treatment Patterns at Week 52 and Week 104
기간: Part 2: From baseline to week 52 and week 104
|
Changes in treatment patterns including use of SCS, ICS, other asthma therapies, and rescue medication. Treatment escalation (for example [e.g.], ICS dose changes, addition of asthma therapies, or biologic prescription), treatment adherence, and treatment persistence will be assessed from baseline to Week 52 and Week 104 in participants with Asthma. |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Changes in Physician Global Assessment of Asthma Severity, Symptom Control and Comorbidities (PhGIS)
기간: Part 2: From baseline to week 52 and week 104
|
Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity. |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Participant Survey Using the PGIS scale
기간: Part 2: At Weeks 52 and 104
|
The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Physician Survey Using the PhGIS Scale
기간: Part 2: At Weeks 52 and 104
|
Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Changes in Physician-reported HCRU (Hospitalizations, Outpatient and Emergency Visits)
기간: Part 2: From baseline to week 52 and week 104
|
Data about HCRU associated with medical encounters will be collected by physicians from medical records. The data collected will include setting, department, type of specialist, the reasons and duration of hospitalizations, outpatient and emergency room (ER) visits. |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Changes in Patient-Reported Outcomes to Characterize Disease Evolution
기간: Part 2: At Weeks 52 and 104
|
PROs used will include but not limited to ACQ-5, mini-AQLQ. ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), Mean of the five responses is the overall score. Scores are then classified into three groups as having well-controlled asthma (score <= 0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). AQLQ includes 32 items, The mini-AQLQ is a reduced version of the AQLQ which includes 15 items. The questions correspond to 4 dimensions of health: symptoms (5 items), limitation of usual activities (4 items), emotional function (3 items) and environmental stimuli (3 items). The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Changes in Participant Survey Response
기간: Part 2: From baseline to week 52 and week 104
|
Participant survey collecting demographics, clinical characteristics, disease burden, health status, treatment experiences, medication use and burden, work and school impacts, lifestyle and environmental influences, impacts on daily life, PGIS for each comorbidity and burden of comorbidities, inhaled and systemic corticosteroid burden (frequency of use, routes of administration, treatment satisfaction), and HCRU office visits, hospitalizations, outpatient and emergency visits will be collected from medical records. |
Part 2: From baseline to week 52 and week 104
|
공동 작업자 및 조사자
협력자
협력자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
기타 연구 ID 번호
- PIR21191
- 2025-524916-13-00 (씨티스)
- U1111-1336-5183 (레지스트리 식별자: ICTRP)
- 2025 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .